Swiss CDMO Sigfried has been on a growth jag over the last decade. | Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience.

Affiliates of funds advised by SK Capital Partners, LP ("SK Capital"), a private investment firm focused on the life sciences, specialty materials, and ingredients sectors announced today they have ...

Shares in Swiss contract-drug manufacturer Siegfried Holding climbed after the company said it struck agreements to buy sites in the U.S., expanding its footprint in the world's largest pharmaceutical ...

Siegfried, a global CDMO for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital ...